A nanomedicine approach to treat autoimmune disease leverages a natural differentiation pathway of T regulatory-1 (TR1) cells.
Time: 2:30 pm
day: Day One
- T-follicular helper (TFH) cells can serve as in vivo precursors of TR1 cells in humans and in mice
- Complete differentiation of TR1 effector function requires the transcription factor Blimp-1 (Prdm1)
- Navacims, a pMHC-II nanomedicine platform induce TFH expansion and differentiation to immunomodulatory TR1 cells